In retrospect: root-cause analysis of structure-activity relationships in IRAK4 inhibitor zimlovisertib (PF-06650833)
Materials and methods Reagents and cell-line DPPH, ABTS, MTT, LPS, DMSO, Curcumin and SOD kit were products purchased from Merck SA (Pty) Ltd
Zoi V, Kyritsis AP, Galani V, Lazari D, Sioka C, Voulgaris S, et al
In rat studies, BPC-157 demonstrated healing effects in various colitis models, including cysteamine-induced colitis, improved intestinal anastomosis healing, and promoted closure of gastrointestinal fistulascomplications relevant to Crohn's disease.[4][5][3] The proposed mechanisms include interaction with the nitric oxide system, angiogenic effects, endothelium protection, and modulation of growth factor expression.[1][6] Critical limitations include the lack of published results from controlled human trials, absence of FDA approval, and concerns about products being sold online without regulatory oversight.[2] The peptide was temporarily banned by the World Anti-Doping Agency in 2022, though it is not currently listed as banned.[2] Given these limitations, BPC-157 cannot be recommended as standard therapy for ulcerative colitis or Crohn's disease based on current evidence
